$ARQT
Arcutis Biotherapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000178730622000071 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $2.961M $725.0K $0.00
YoY Change
Cost Of Revenue $485.0K $269.0K
YoY Change
Gross Profit $2.476M $456.0K
YoY Change
Gross Profit Margin 83.62% 62.9%
Selling, General & Admin $37.02M $35.47M $18.73M
YoY Change 97.69% 115.33% 179.94%
% of Gross Profit 1495.27% 7779.17%
Research & Development $33.88M $69.73M $52.56M
YoY Change -35.54% 71.73% 92.03%
% of Gross Profit 1368.21% 15291.89%
Depreciation & Amortization $347.0K $157.0K $136.0K
YoY Change 155.15% 35.34% 353.33%
% of Gross Profit 14.01% 34.43%
Operating Expenses $70.90M $105.5M $71.29M
YoY Change -0.54% 84.79% 109.27%
Operating Profit -$68.42M -$104.7M
YoY Change 83.52%
Interest Expense -$6.915M $4.899M
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.320M -$2.961M -$40.00K
YoY Change -8400.0% -3121.43% -366.67%
Pretax Income -$72.02M -$107.7M -$71.33M
YoY Change 0.97% 89.03% 109.47%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$72.02M -$107.7M -$71.33M
YoY Change 0.97% 89.03% 109.48%
Net Earnings / Revenue -2432.25% -14856.41%
Basic Earnings Per Share -$1.89
Diluted Earnings Per Share -$1.18 -$1.89 -$1.420M
COMMON SHARES
Basic Shares Outstanding 60.93M shares 51.56M shares 50.30M shares
Diluted Shares Outstanding 57.09M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $409.6M $477.0M $387.1M
YoY Change 5.82% 29.87% 36.08%
Cash & Equivalents $53.64M $81.54M $96.45M
Short-Term Investments $355.9M $395.4M $290.6M
Other Short-Term Assets $11.85M $13.02M $15.35M
YoY Change -22.84% -7.92% 96.82%
Inventory $7.514M $4.307M $0.00
Prepaid Expenses
Receivables $8.458M $2.431M $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $437.4M $496.7M $402.8M
YoY Change 8.6% 30.11% 37.55%
LONG-TERM ASSETS
Property, Plant & Equipment $1.881M $1.939M $2.261M
YoY Change -16.81% -5.18% 12.15%
Goodwill
YoY Change
Intangibles $7.188M $7.375M $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.00K $78.00K $78.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $11.87M $12.20M $5.379M
YoY Change 120.64% 132.82% -1.18%
TOTAL ASSETS
Total Short-Term Assets $437.4M $496.7M $402.8M
Total Long-Term Assets $11.87M $12.20M $5.379M
Total Assets $449.3M $508.9M $408.2M
YoY Change 10.08% 31.5% 36.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.827M $8.666M $7.353M
YoY Change 20.05% 77.91% 2.98%
Accrued Expenses $28.32M $27.80M $25.54M
YoY Change 10.9% 100.25% 65.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.81M $37.10M $33.33M
YoY Change 13.45% 94.68% 47.45%
LONG-TERM LIABILITIES
Long-Term Debt $197.8M $196.8M $72.35M
YoY Change 173.35%
Other Long-Term Liabilities $0.00 $0.00 $25.00K
YoY Change -100.0% -100.0% -69.51%
Total Long-Term Liabilities $197.8M $196.8M $72.38M
YoY Change 173.26% 634587.1% 88162.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.81M $37.10M $33.33M
Total Long-Term Liabilities $197.8M $196.8M $72.38M
Total Liabilities $239.7M $238.1M $110.5M
YoY Change 116.97% 891.71% 299.58%
SHAREHOLDERS EQUITY
Retained Earnings -$719.8M -$647.7M -$408.3M
YoY Change 76.29% 92.2% 102.13%
Common Stock $6.000K $6.000K $5.000K
YoY Change 20.0% 20.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $209.6M $270.8M $297.7M
YoY Change
Total Liabilities & Shareholders Equity $449.3M $508.9M $408.2M
YoY Change 10.08% 31.5% 36.84%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$72.02M -$107.7M -$71.33M
YoY Change 0.97% 89.03% 109.48%
Depreciation, Depletion And Amortization $347.0K $157.0K $136.0K
YoY Change 155.15% 35.34% 353.33%
Cash From Operating Activities -$71.06M -$67.70M -$51.71M
YoY Change 37.43% 65.58% 58.76%
INVESTING ACTIVITIES
Capital Expenditures $123.0K -$22.96M -$261.0K
YoY Change -147.13% 16656.2% 74.0%
Acquisitions
YoY Change
Other Investing Activities $42.32M -$174.3M $23.76M
YoY Change 78.13% -4931.1% -131.37%
Cash From Investing Activities $42.20M -$197.3M $23.50M
YoY Change 79.59% -5783.15% -130.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 962.0K 285.0M 72.88M
YoY Change -98.68% 452263.49% -43.67%
NET CHANGE
Cash From Operating Activities -71.06M -67.70M -51.71M
Cash From Investing Activities 42.20M -197.3M 23.50M
Cash From Financing Activities 962.0K 285.0M 72.88M
Net Change In Cash -27.90M 20.03M 44.67M
YoY Change -162.46% -153.63% 113.53%
FREE CASH FLOW
Cash From Operating Activities -$71.06M -$67.70M -$51.71M
Capital Expenditures $123.0K -$22.96M -$261.0K
Free Cash Flow -$71.19M -$44.74M -$51.45M
YoY Change 38.37% 9.8% 58.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001787306
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39186
dei Entity Registrant Name
EntityRegistrantName
ARCUTIS BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2974255
dei Entity Address Address Line1
EntityAddressAddressLine1
3027 Townsgate Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Westlake Village
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91361
dei City Area Code
CityAreaCode
805
dei Local Phone Number
LocalPhoneNumber
418-5006
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
ARQT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60927824 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81543000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96449000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1234000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1542000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2431000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
395420000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
290610000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
4307000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11784000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14172000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
496719000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
402773000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1939000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2261000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7375000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2803000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3040000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000 usd
CY2022Q3 us-gaap Assets
Assets
508914000 usd
CY2021Q4 us-gaap Assets
Assets
408152000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8666000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7353000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27797000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25540000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
639000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
433000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
37102000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33326000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4285000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4774000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
196753000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
72350000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
25000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
238140000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
110475000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60927208 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50345755 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60908641 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50255614 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
920109000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
706233000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1596000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-255000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-647745000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408306000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
270774000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
297677000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
508914000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
408152000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
725000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
725000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2022Q3 arqt Cost Of Sales
CostOfSales
269000 usd
CY2021Q3 arqt Cost Of Sales
CostOfSales
0 usd
arqt Cost Of Sales
CostOfSales
269000 usd
arqt Cost Of Sales
CostOfSales
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69731000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40604000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148558000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93000000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35473000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53028962 shares
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16474000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
85101000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42243000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
105473000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
57078000 usd
us-gaap Operating Expenses
OperatingExpenses
233928000 usd
us-gaap Operating Expenses
OperatingExpenses
135243000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-104748000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-57078000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-233203000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-135243000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1938000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2501000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
213000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4899000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
8737000 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2961000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
98000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6236000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
213000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-107709000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-56980000 usd
us-gaap Net Income Loss
NetIncomeLoss
-239439000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135030000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-344000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1341000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108053000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56962000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240780000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135046000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.75
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57091743 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57091743 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50097851 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50097851 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53028962 shares
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
325000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49136768 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49136768 shares
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
270621000 usd
CY2021Q1 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
53000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8503000 usd
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
44000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-36042000 usd
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
450994000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
710000 usd
CY2021Q2 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
52000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
478000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4340000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-78000 usd
CY2022Q1 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
25000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-42008000 usd
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
414488000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000 usd
CY2021Q3 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
43000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5363000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-56980000 usd
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
362995000 usd
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
297677000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
260000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6533000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-765000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-64324000 usd
CY2022Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
253772000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
156000 usd
CY2022Q2 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
20000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
976000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8096000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-232000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-67406000 usd
CY2022Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
195382000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161657000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12468000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494000 usd
CY2022Q3 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
37000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8789000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-344000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-107709000 usd
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
270774000 usd
us-gaap Net Income Loss
NetIncomeLoss
-239439000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135030000 usd
us-gaap Depreciation
Depreciation
462000 usd
us-gaap Depreciation
Depreciation
318000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
237000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
234000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
29630000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-89000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2569000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1590000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23418000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18206000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2431000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4307000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2299000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6115000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1383000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2146000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
577000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1220000 usd
arqt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-283000 usd
arqt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
266000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-186650000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-122918000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
377301000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
244268000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
271061000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
145550000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
734000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
15450000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
arqt Payment Of Milestone For Intangible
PaymentOfMilestoneForIntangible
7500000 usd
arqt Payment Of Milestone For Intangible
PaymentOfMilestoneForIntangible
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129400000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99452000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1098000 usd
arqt Proceeds From Issuance Of At The Market Offering
ProceedsFromIssuanceOfAtTheMarketOffering
14455000 usd
arqt Proceeds From Issuance Of At The Market Offering
ProceedsFromIssuanceOfAtTheMarketOffering
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161592000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
207490000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
976000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
478000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
125000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2187000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300836000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
209066000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15214000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13304000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97991000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66624000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82777000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53320000 usd
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
6923000 usd
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
0 usd
arqt Acquired In Process Research And Development Obtained In Exchange For Issuance Of Common Stock
AcquiredInProcessResearchAndDevelopmentObtainedInExchangeForIssuanceOfCommonStock
12468000 usd
arqt Acquired In Process Research And Development Obtained In Exchange For Issuance Of Common Stock
AcquiredInProcessResearchAndDevelopmentObtainedInExchangeForIssuanceOfCommonStock
0 usd
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-647700000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408300000 usd
CY2022Q3 arqt Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
478200000 usd
CY2021Q4 arqt Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
388600000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense, and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
14600000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2022Q3 arqt Intangible Assets Milestone Payment
IntangibleAssetsMilestonePayment
7500000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></div>
CY2021Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
476963000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
387059000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81543000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
81543000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
397016000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1596000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
395420000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96449000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
96449000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
290865000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
255000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
290610000 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3493000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
116000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
698000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
0 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
4307000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q3 arqt Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
1967000 usd
CY2021Q4 arqt Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
0 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1846000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
518000 usd
CY2022Q3 arqt Prepaid Clinical Trial Test Costs Current
PrepaidClinicalTrialTestCostsCurrent
454000 usd
CY2021Q4 arqt Prepaid Clinical Trial Test Costs Current
PrepaidClinicalTrialTestCostsCurrent
5629000 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7517000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8025000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11784000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14172000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11538000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9130000 usd
CY2022Q3 arqt Clinical Trial Accrual Current
ClinicalTrialAccrualCurrent
9766000 usd
CY2021Q4 arqt Clinical Trial Accrual Current
ClinicalTrialAccrualCurrent
13217000 usd
CY2022Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
853000 usd
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
0 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5640000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3193000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27797000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25540000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2932000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2793000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
993000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
532000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1939000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2261000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
157000 usd
us-gaap Depreciation
Depreciation
462000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
116000 usd
us-gaap Depreciation
Depreciation
318000 usd
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
0 usd
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
0 usd
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
234000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
965000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
994000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1025000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1054000 usd
CY2022Q3 arqt Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
1740000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6012000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1088000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4924000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
639000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4285000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4924000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
186000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
530000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
171000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
516000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
547000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2022Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
2900000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
2100000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
600000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
600000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000 usd
CY2022Q3 arqt Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
1113000 usd
CY2021Q4 arqt Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
0 usd
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4360000 usd
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2650000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
196753000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
72350000 usd
CY2022Q3 arqt Common Stock Voting Rights Number Of Votes Per Share
CommonStockVotingRightsNumberOfVotesPerShare
1 vote
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11461564 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8161157 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2020Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5757957 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.06
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34887000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2133150 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.20
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
290865 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115789 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4413 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
26.93
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7480040 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M19D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28324000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3323627 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M29D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
24854000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5100000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
20200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.13
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8789000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5363000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23418000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18206000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9122294 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6207572 shares

Files In Submission

Name View Source Status
0001787306-22-000071-index-headers.html Edgar Link pending
0001787306-22-000071-index.html Edgar Link pending
0001787306-22-000071.txt Edgar Link pending
0001787306-22-000071-xbrl.zip Edgar Link pending
arcutis-ducentisredacted.htm Edgar Link pending
arcutis-ducentisredacted001.jpg Edgar Link pending
arcutis-ducentisredacted002.jpg Edgar Link pending
arcutis-ducentisredacted003.jpg Edgar Link pending
arcutis-ducentisredacted004.jpg Edgar Link pending
arcutis-ducentisredacted005.jpg Edgar Link pending
arcutis-ducentisredacted006.jpg Edgar Link pending
arcutis-ducentisredacted007.jpg Edgar Link pending
arcutis-ducentisredacted008.jpg Edgar Link pending
arcutis-ducentisredacted009.jpg Edgar Link pending
arcutis-ducentisredacted010.jpg Edgar Link pending
arcutis-ducentisredacted011.jpg Edgar Link pending
arcutis-ducentisredacted012.jpg Edgar Link pending
arcutis-ducentisredacted013.jpg Edgar Link pending
arcutis-ducentisredacted014.jpg Edgar Link pending
arcutis-ducentisredacted015.jpg Edgar Link pending
arcutis-ducentisredacted016.jpg Edgar Link pending
arcutis-ducentisredacted017.jpg Edgar Link pending
arcutis-ducentisredacted018.jpg Edgar Link pending
arcutis-ducentisredacted019.jpg Edgar Link pending
arcutis-ducentisredacted020.jpg Edgar Link pending
arcutis-ducentisredacted021.jpg Edgar Link pending
arcutis-ducentisredacted022.jpg Edgar Link pending
arcutis-ducentisredacted023.jpg Edgar Link pending
arcutis-ducentisredacted024.jpg Edgar Link pending
arcutis-ducentisredacted025.jpg Edgar Link pending
arcutis-ducentisredacted026.jpg Edgar Link pending
arcutis-ducentisredacted027.jpg Edgar Link pending
arcutis-ducentisredacted028.jpg Edgar Link pending
arcutis-ducentisredacted029.jpg Edgar Link pending
arcutis-ducentisredacted030.jpg Edgar Link pending
arcutis-ducentisredacted031.jpg Edgar Link pending
arcutis-ducentisredacted032.jpg Edgar Link pending
arcutis-ducentisredacted033.jpg Edgar Link pending
arcutis-ducentisredacted034.jpg Edgar Link pending
arcutis-ducentisredacted035.jpg Edgar Link pending
arcutis-ducentisredacted036.jpg Edgar Link pending
arcutis-ducentisredacted037.jpg Edgar Link pending
arcutis-ducentisredacted038.jpg Edgar Link pending
arcutis-ducentisredacted039.jpg Edgar Link pending
arcutis-ducentisredacted040.jpg Edgar Link pending
arcutis-ducentisredacted041.jpg Edgar Link pending
arcutis-ducentisredacted042.jpg Edgar Link pending
arcutis-ducentisredacted043.jpg Edgar Link pending
arcutis-ducentisredacted044.jpg Edgar Link pending
arcutis-ducentisredacted045.jpg Edgar Link pending
arcutis-ducentisredacted046.jpg Edgar Link pending
arcutis-ducentisredacted047.jpg Edgar Link pending
arcutis-ducentisredacted048.jpg Edgar Link pending
arcutis-ducentisredacted049.jpg Edgar Link pending
arcutis-ducentisredacted050.jpg Edgar Link pending
arcutis-ducentisredacted051.jpg Edgar Link pending
arcutis-ducentisredacted052.jpg Edgar Link pending
arcutis-ducentisredacted053.jpg Edgar Link pending
arcutis-ducentisredacted054.jpg Edgar Link pending
arcutis-ducentisredacted055.jpg Edgar Link pending
arcutis-ducentisredacted056.jpg Edgar Link pending
arcutis-ducentisredacted057.jpg Edgar Link pending
arcutis-ducentisredacted058.jpg Edgar Link pending
arcutis-ducentisredacted059.jpg Edgar Link pending
arcutis-ducentisredacted060.jpg Edgar Link pending
arcutis-ducentisredacted061.jpg Edgar Link pending
arcutis-ducentisredacted062.jpg Edgar Link pending
arcutis-ducentisredacted063.jpg Edgar Link pending
arcutis-ducentisredacted064.jpg Edgar Link pending
arcutis-ducentisredacted065.jpg Edgar Link pending
arcutis-ducentisredacted066.jpg Edgar Link pending
arcutis-ducentisredacted067.jpg Edgar Link pending
arcutis-ducentisredacted068.jpg Edgar Link pending
arcutis-ducentisredacted069.jpg Edgar Link pending
arcutis-ducentisredacted070.jpg Edgar Link pending
arcutis-ducentisredacted071.jpg Edgar Link pending
arcutis-ducentisredacted072.jpg Edgar Link pending
arcutis-ducentisredacted073.jpg Edgar Link pending
arcutis-ducentisredacted074.jpg Edgar Link pending
arcutis-ducentisredacted075.jpg Edgar Link pending
arcutis-ducentisredacted076.jpg Edgar Link pending
arcutis-ducentisredacted077.jpg Edgar Link pending
arcutis-ducentisredacted078.jpg Edgar Link pending
arcutis-ducentisredacted079.jpg Edgar Link pending
arcutis-ducentisredacted080.jpg Edgar Link pending
arcutis-ducentisredacted081.jpg Edgar Link pending
arcutis-ducentisredacted082.jpg Edgar Link pending
arcutis-ducentisredacted083.jpg Edgar Link pending
arcutis-ducentisredacted084.jpg Edgar Link pending
arcutis-ducentisredacted085.jpg Edgar Link pending
arcutis-ducentisredacted086.jpg Edgar Link pending
arcutis-ducentisredacted087.jpg Edgar Link pending
arcutis-ducentisredacted088.jpg Edgar Link pending
arcutis-ducentisredacted089.jpg Edgar Link pending
arcutis-ducentisredacted090.jpg Edgar Link pending
arcutis-ducentisredacted091.jpg Edgar Link pending
arcutis-ducentisredacted092.jpg Edgar Link pending
arcutis-ducentisredacted093.jpg Edgar Link pending
arcutis-ducentisredacted094.jpg Edgar Link pending
arcutis-ducentisredacted095.jpg Edgar Link pending
arcutis-ducentisredacted096.jpg Edgar Link pending
arcutis-ducentisredacted097.jpg Edgar Link pending
arcutis-ducentisredacted098.jpg Edgar Link pending
arcutis-ducentisredacted099.jpg Edgar Link pending
arcutis-ducentisredacted100.jpg Edgar Link pending
arcutis-ducentisredacted101.jpg Edgar Link pending
arcutis-ducentisredacted102.jpg Edgar Link pending
arcutis-ducentisredacted103.jpg Edgar Link pending
arcutis-ducentisredacted104.jpg Edgar Link pending
arcutis-ducentisredacted105.jpg Edgar Link pending
arcutis-ducentisredacted106.jpg Edgar Link pending
arcutis-ducentisredacted107.jpg Edgar Link pending
arcutis-ducentisredacted108.jpg Edgar Link pending
arcutis-ducentisredacted109.jpg Edgar Link pending
arcutis-ducentisredacted110.jpg Edgar Link pending
arcutis-ducentisredacted111.jpg Edgar Link pending
arcutis-ducentisredacted112.jpg Edgar Link pending
arcutis-ducentisredacted113.jpg Edgar Link pending
arcutis-ducentisredacted114.jpg Edgar Link pending
arcutis-ducentisredacted115.jpg Edgar Link pending
arcutis-ducentisredacted116.jpg Edgar Link pending
arcutis-ducentisredacted117.jpg Edgar Link pending
arcutis-ducentisredacted118.jpg Edgar Link pending
arcutis-ducentisredacted119.jpg Edgar Link pending
arcutis-ducentisredacted120.jpg Edgar Link pending
arcutis-ducentisredacted121.jpg Edgar Link pending
arcutis-ducentisredacted122.jpg Edgar Link pending
arcutis-ducentisredacted123.jpg Edgar Link pending
arcutis-ducentisredacted124.jpg Edgar Link pending
arcutis-ducentisredacted125.jpg Edgar Link pending
arcutis-ducentisredacted126.jpg Edgar Link pending
arcutis-ducentisredacted127.jpg Edgar Link pending
arcutis-ducentisredacted128.jpg Edgar Link pending
arcutis-ducentisredacted129.jpg Edgar Link pending
arcutis-ducentisredacted130.jpg Edgar Link pending
arcutis-ducentisredacted131.jpg Edgar Link pending
arcutis-ducentisredacted132.jpg Edgar Link pending
arcutis-ducentisredacted133.jpg Edgar Link pending
arcutis-ducentisredacted134.jpg Edgar Link pending
arcutis-ducentisredacted135.jpg Edgar Link pending
arcutis-ducentisredacted136.jpg Edgar Link pending
arcutis-ducentisredacted137.jpg Edgar Link pending
arcutis-ducentisredacted138.jpg Edgar Link pending
arcutis-ducentisredacted139.jpg Edgar Link pending
arcutis-ducentisredacted140.jpg Edgar Link pending
arqt-20220930.htm Edgar Link pending
arqt-20220930.xsd Edgar Link pending
exhibit102amendmentno1supp.htm Edgar Link pending
exhibit311ceoq32022.htm Edgar Link pending
exhibit312cfoq32022.htm Edgar Link pending
exhibit321ceocfoq32022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
arqt-20220930_def.xml Edgar Link unprocessable
arqt-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arqt-20220930_pre.xml Edgar Link unprocessable
arqt-20220930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
arqt-20220930_cal.xml Edgar Link unprocessable